Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-02-21

FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZUBSOLV (buprenorphine/naloxone) from Orexo US, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZUBSOLV (Buprenorphine hydrochloride and naloxone hydrochloride)

Snippet

SUPPL AP for ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)